Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience
Background/Aim. Standard treatment options for the first-line treatment of metastatic colorectal carcinoma (mCRC) are 5-fluorouracil, folinic acid, oxaliplatin (FOL-FOX4)/capecitabine (CapOx), plus bevacizumab (bev) and 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) plus bev. The aim of this...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2022-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502100053J.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849703988731052032 |
|---|---|
| author | Jungić Saša Tubić Biljana Berendika Jelena Gojković Zdenka Rakita Ivanka Vještica Milka Đokanović Dejan Gajanin Radoslav |
| author_facet | Jungić Saša Tubić Biljana Berendika Jelena Gojković Zdenka Rakita Ivanka Vještica Milka Đokanović Dejan Gajanin Radoslav |
| author_sort | Jungić Saša |
| collection | DOAJ |
| description | Background/Aim. Standard treatment options for the first-line treatment of metastatic colorectal carcinoma (mCRC) are 5-fluorouracil, folinic acid, oxaliplatin (FOL-FOX4)/capecitabine (CapOx), plus bevacizumab (bev) and 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) plus bev. The aim of this study was to compare overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in patients with mCRC who were treated in the first line with FOLFIRI/bev vs. FOLFOX4/bev. At the same time, the aim was also to compare the safety profile in the observed groups of patients and to investigate optimal treatment duration and characteristics of patients who had the best treatment outcomes. Methods. The retrospective-prospective study included patients with mCRC treated with chemotherapy protocols for the first line in combination with bev (FOLFOX4/bev, respectively, FOLFIRI/bev). Treatment efficacy was evaluated on the basis of ORR, PFS, and OS, and the safety of treatment was evaluated by monitoring adverse drug reactions (ADR). Results. ORR was 70% in the FOLFIRI/bev group and 50% in the FOL-FOX4/bev group. Median PFS for FOLFIRI/bev (n = 30) and for FOLFOX4/bev (n = 30) was 15.6 months and 12.1 months, respectively [hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.47–1.53; p = 0.5591]. Median OS for FOLFIRI/bev and for FOLFOX4/bev was 24.7 months and 19.9 months, respectively (HR 0.67; 95% CI 0.37–1.23; p = 0.1552). In both patient groups, the patients who received more than 9 cycles of induction therapy had better treatment response compared with patients who received less than 9 cycles of therapy. In the FOLFOX4/bev group, PFS was 16.9 vs. 9.7 months, and OS was 22.1 vs. 17.6 months, respectively. In the FOLFIRI/bev group, PFS was 9 months for patients who received less than 9 cycles of therapy vs. 18.8 months for patients who received more than 9 cycles, and OS was 18.0 months vs. 27.7 months, respectively. ADR grade 3 and 4 had 7% of the patients in the FOLFIRI/bev group vs. 27% in the FOLFOX4/bev group. Conclusion. Patients who received FOLFIRI/bev compared to those treated with FOLFOX4/bev had better ORR (70% vs. 50 %, respectively), PFS (15.6 months vs. 12.1 months, respectively), and OS (24.7 months vs. 19.9 months, respectively). In both patient groups, the patients who received induction therapy for 4–6 months (more than 9 cycles of therapy) had a better treatment response. |
| format | Article |
| id | doaj-art-0644a1e73d9e404cbd2df6715154bbe7 |
| institution | DOAJ |
| issn | 0042-8450 2406-0720 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-0644a1e73d9e404cbd2df6715154bbe72025-08-20T03:16:57ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202022-01-0179879680410.2298/VSP200924053J0042-84502100053JOptimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experienceJungić Saša0Tubić Biljana1Berendika Jelena2Gojković Zdenka3Rakita Ivanka4Vještica Milka5Đokanović Dejan6Gajanin Radoslav7University Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and Herzegovina + University of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and Herzegovina + Agency for Medicines and Medical Devices of Bosnia and Herzegovina, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and Herzegovina; †University of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and Herzegovina + University of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity Clinical Center of the Republic of Srpska, Oncology Clinic, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaUniversity of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and Herzegovina + University of Banjaluka, Faculty of Medicine, Banjaluka, Republic of Srpska, Bosnia and HerzegovinaBackground/Aim. Standard treatment options for the first-line treatment of metastatic colorectal carcinoma (mCRC) are 5-fluorouracil, folinic acid, oxaliplatin (FOL-FOX4)/capecitabine (CapOx), plus bevacizumab (bev) and 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) plus bev. The aim of this study was to compare overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in patients with mCRC who were treated in the first line with FOLFIRI/bev vs. FOLFOX4/bev. At the same time, the aim was also to compare the safety profile in the observed groups of patients and to investigate optimal treatment duration and characteristics of patients who had the best treatment outcomes. Methods. The retrospective-prospective study included patients with mCRC treated with chemotherapy protocols for the first line in combination with bev (FOLFOX4/bev, respectively, FOLFIRI/bev). Treatment efficacy was evaluated on the basis of ORR, PFS, and OS, and the safety of treatment was evaluated by monitoring adverse drug reactions (ADR). Results. ORR was 70% in the FOLFIRI/bev group and 50% in the FOL-FOX4/bev group. Median PFS for FOLFIRI/bev (n = 30) and for FOLFOX4/bev (n = 30) was 15.6 months and 12.1 months, respectively [hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.47–1.53; p = 0.5591]. Median OS for FOLFIRI/bev and for FOLFOX4/bev was 24.7 months and 19.9 months, respectively (HR 0.67; 95% CI 0.37–1.23; p = 0.1552). In both patient groups, the patients who received more than 9 cycles of induction therapy had better treatment response compared with patients who received less than 9 cycles of therapy. In the FOLFOX4/bev group, PFS was 16.9 vs. 9.7 months, and OS was 22.1 vs. 17.6 months, respectively. In the FOLFIRI/bev group, PFS was 9 months for patients who received less than 9 cycles of therapy vs. 18.8 months for patients who received more than 9 cycles, and OS was 18.0 months vs. 27.7 months, respectively. ADR grade 3 and 4 had 7% of the patients in the FOLFIRI/bev group vs. 27% in the FOLFOX4/bev group. Conclusion. Patients who received FOLFIRI/bev compared to those treated with FOLFOX4/bev had better ORR (70% vs. 50 %, respectively), PFS (15.6 months vs. 12.1 months, respectively), and OS (24.7 months vs. 19.9 months, respectively). In both patient groups, the patients who received induction therapy for 4–6 months (more than 9 cycles of therapy) had a better treatment response.http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502100053J.pdfclinical protocolscolorectal neoplasmsdrug-related side effects and adverse reactionsduration of therapyfolfox protocolifl protocolneoplasm metastasissurvival |
| spellingShingle | Jungić Saša Tubić Biljana Berendika Jelena Gojković Zdenka Rakita Ivanka Vještica Milka Đokanović Dejan Gajanin Radoslav Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience Vojnosanitetski Pregled clinical protocols colorectal neoplasms drug-related side effects and adverse reactions duration of therapy folfox protocol ifl protocol neoplasm metastasis survival |
| title | Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience |
| title_full | Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience |
| title_fullStr | Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience |
| title_full_unstemmed | Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience |
| title_short | Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience |
| title_sort | optimal duration of therapy in the first line treatment of metastatic colorectal cancer single center experience |
| topic | clinical protocols colorectal neoplasms drug-related side effects and adverse reactions duration of therapy folfox protocol ifl protocol neoplasm metastasis survival |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502100053J.pdf |
| work_keys_str_mv | AT jungicsasa optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT tubicbiljana optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT berendikajelena optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT gojkoviczdenka optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT rakitaivanka optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT vjesticamilka optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT đokanovicdejan optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience AT gajaninradoslav optimaldurationoftherapyinthefirstlinetreatmentofmetastaticcolorectalcancersinglecenterexperience |